|
Medical News Thailand to Present Vaccine Results From Phase III HIV Vaccine Trial During XV International AIDS ConferenceJune 9, 2004 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Researchers from Thailand are expected to present results from the world's largest Phase III HIV vaccine trial at the XV International AIDS Conference, which is scheduled for July 11-16 in Bangkok, Thailand, Thailand's Nation reports (Nation, 6/8). The trial is testing Brisbane, Calif.-based biotechnology company VaxGen's experimental vaccine AIDSVAX in conjunction with Aventis Pasteur's ALVAC among 16,000 HIV-negative volunteers from Thailand's Rayong and Chon Buri provinces. In the five-year trial, which began in September 2003, AIDSVAX is being used as a booster for the ALVAC vaccine (Kaiser Daily HIV/AIDS Report, 1/16). Charal Trinvuthipong, Thailand's Department of Disease Control director-general, on Monday said that researchers at the conference would hear details about the Phase III trial's progress, according to the Nation (Nation, 6/8). Although AIDSVAX failed to protect against HIV infection in trials to test its individual usefulness, researchers hope that combining the two vaccines will provide a protective effect, the Bangkok Post reports (Bangkok Post, 6/5). Back to other news for June 9, 2004
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
|
|